Nir Salomon, Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center and Co-founder and Head of R&D at Evinature, is hitting the road for a string of lectures in USA’s leading medical centers on  20.4 (Indiana), 27.4 (Houston),  28.4 (Oklahoma), 6.5 (Chicago), 17.5 (Washington), 24.5 (Irving). Attendees can expect an in-depth and informative discussion about the role of integrative therapies of IBD, how the immersion of alternative medicine and traditional medicine plays a key part in optimizing healthcare for IBD patients, and how  Evinature is changing the game through tailored protocols, guided care, and evidence-based treatment.  

Following his highly successful talk at ISCARE in Prague, the largest IBD center in the Czech Republic, Nir is taking his expertise in the field of integrative gastroenterology to the US at medical centers at the University of Minnesota, the University of Indiana, the University of Oklahoma, the University of Chicago, University of California at Irving, Washington University at St. Louis, Vanderbilt University in Nashville, Children's hospital in Los Angeles, British Columbia Children's Hospital, Mayo Clinic, Cedars Sinai, University of Wisconsin, Houston Methodist Weill Cornell Medical College, Lenox Hill Hospital in New York, New York Gastro Association (a private organization) affiliated with Mount Sinai, Cleveland Clinic, and the University of Michigan.   

“I am thrilled about the opportunity to meet fellow medical professionals and to share my knowledge in the field of integrative gastroenterology,” Nir says, “By integrating clinically proven nutraceuticals into standard medical care, patients with IBD can benefit from personalized treatments based on scientific evidence, which may improve their overall well-being. It is with great privilege that I look forward to sharing our research data and experience with colleagues from leading IBD centers throughout the United States. Equally, I'm excited to learn from their viewpoints and opinions, which could broaden our perspective and help promote this unique clinical approach”  

Evinature is establishing a network of leading medical centers across the USA to collaboratively research CurQD and other non-pharmaceutical treatments for gastrointestinal diseases. These collaborations are helping more patients access effective, safe, and affordable natural treatments that can be integrated into standard clinical practice under medical supervision and follow-up. Evinature is proud to work together with leading doctors from across the USA to promote a better quality of life for IBD patients.    

Joining Nir as a key opinion leader is American gastroenterologist David Rubin, University of Chicago’s Professor of Medicine and Section Chief at the Section of Gastroenterology, Hepatology, and Nutrition.  

Nir Salomon established the Integrative Gastroenterology unit at Sheba Medical Center and collaborated with Professor Shomron Ben-Horin on a research project for ten years to develop nutraceutical therapies for Inflammatory Bowel Disease. They conducted successful clinical trials from 2011 to 2022 on the use of CurQD®, a combination of curcumin and Qing Dai, on patients with UC.

Salomon presented his international, investigator-initiated placebo-controlled trial on CurQD® at the Crohn’s and Colitis Foundation of America (CCFA), where it won the Poster of Distinction award.  

In 2021, Salomon and Ben-Horin founded Evinature with Sheba Medical Center to provide affordable and effective therapies to IBD patients. Salomon is a speaker at medical conferences, promoting integrative and evidence-based therapies. He is also creating a network of leading IBD doctors globally to facilitate collaborative research projects in the field of nutraceuticals to enhance medical accessibility for patients around the world.